Conmed (CNMD) Tops Q4 EPS by 8c, Offers Guidance

Conmed (NASDAQ: CNMD) reported Q4 EPS of $0.84, $0.08 better than the analyst estimate of $0.76. Revenue for the quarter came in at $252.8 million versus the consensus estimate of $262.94 million.

GUIDANCE:

Conmed sees FY2021 EPS of $2.85-$3.05, versus the consensus of $3.02. Conmed sees FY2021 revenue of $975-1020 million, versus the consensus of $1020 million.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• Arrive AI and DXC Technology partner to bring delivery tech to factories